From: Comparison of clinical features and outcomes between patients with early and delayed lupus nephritis
Variables | Total (nā=ā171) | Patients with early lupus nephritis (nā=ā106) | Patients with delayed lupus nephritis (nā=ā65) | p-value |
---|---|---|---|---|
Kidney histopathology data | ||||
Lupus nephritis class | ||||
āāClass I | 3 (1.8) | 0 (0.0) | 3 (4.6) | 0.053 |
āāClass IIa | 7 (4.1) | 4 (3.8) | 3 (4.6) | 0.999 |
āāClass IIIa | 57 (33.3) | 35 (33.0) | 22 (33.8) | 0.801 |
āāClass IVa | 84 (49.1) | 53 (50.0) | 31 (47.7) | 0.770 |
āāClass Va | 42 (24.6) | 29 (27.4) | 13 (20.0) | 0.279 |
āāClass VI | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0.999 |
Activity/Chronicity | ||||
āāActivity index | 7.0 (2.0ā11.8) | 7.0 (2.0ā11.0) | 8.0 (3.0ā12.0) | 0.323 |
Chronicity index, n (%) | Ā | Ā | Ā | 0.007 |
ā0ā1 | 104 (60.8) | 71 (67.0) | 33 (50.8) | Ā |
ā2ā3 | 51 (29.8) | 30 (28.3) | 21 (32.3) | Ā |
ā4ā5 | 13 (7.6) | 4 (3.8) | 9 (13.8) | Ā |
ā6 | 3 (1.8) | 1 (0.9) | 2 (3.1) | Ā |
Prior immunosuppressive agent use | ||||
āāGlucocorticoids | 64 (37.4) | 0 (0.0) | 64 (98.5) | <ā0.001 |
āāCyclophosphamide | 1 (0.6) | 0 (0.0) | 1 (1.5) | 0.380 |
āāMycophenolate mofetil | 2 (1.2) | 0 (0.0) | 2 (3.1) | 0.143 |
āāTacrolimus | 1 (0.6) | 0 (0.0) | 1 (1.5) | 0.380 |
āāCyclosporine | 2 (1.2) | 0 (0.0) | 2 (3.1) | 0.143 |
āāAzathioprine | 10 (5.8) | 0 (0.0) | 10 (15.4) | <ā0.001 |
āāMethotrexate | 3 (1.8) | 0 (0.0) | 3 (4.6) | 0.053 |
āāHydroxychloroquine | 44 (25.7) | 0 (0.0) | 44 (67.7) | <ā0.001 |